Boule Diagnostics AB (publ) (BOUL.ST)
SEK 8.3
(3.71%)
SEK 8.3
(3.71%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 24.97 Million SEK | 96.24% |
| 2022 | 12.72 Million SEK | -45.31% |
| 2021 | 23.27 Million SEK | 148.52% |
| 2020 | -47.96 Million SEK | -227.74% |
| 2019 | 37.54 Million SEK | -8.49% |
| 2018 | 41.03 Million SEK | 10.18% |
| 2017 | 37.23 Million SEK | 3.35% |
| 2016 | 36.03 Million SEK | 134.71% |
| 2015 | 15.35 Million SEK | -49.27% |
| 2014 | 30.26 Million SEK | 143.16% |
| 2013 | -70.12 Million SEK | -739.89% |
| 2012 | 10.95 Million SEK | -6.42% |
| 2011 | 11.71 Million SEK | -38.01% |
| 2010 | 18.89 Million SEK | 279.09% |
| 2009 | -10.54 Million SEK | -90.09% |
| 2008 | -5.54 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 9.8 Million SEK | 15.61% |
| 2024 Q3 | -229.2 Million SEK | -14225.0% |
| 2024 Q2 | -1.6 Million SEK | -116.33% |
| 2023 Q3 | 4.6 Million SEK | 12.2% |
| 2023 Q4 | 8.47 Million SEK | 84.28% |
| 2023 FY | 24.97 Million SEK | 96.24% |
| 2023 Q1 | 7.9 Million SEK | 169.81% |
| 2023 Q2 | 4.1 Million SEK | -48.1% |
| 2022 Q1 | 4.6 Million SEK | -73.37% |
| 2022 Q3 | 2.4 Million SEK | -17.24% |
| 2022 FY | 12.72 Million SEK | -45.31% |
| 2022 Q4 | 2.92 Million SEK | 22.0% |
| 2022 Q2 | 2.9 Million SEK | -36.96% |
| 2021 Q3 | 7.1 Million SEK | 607.14% |
| 2021 Q2 | -1.4 Million SEK | -566.67% |
| 2021 Q4 | 17.27 Million SEK | 143.27% |
| 2021 FY | 23.27 Million SEK | 148.52% |
| 2021 Q1 | 300 Thousand SEK | 100.92% |
| 2020 Q4 | -32.56 Million SEK | -261.22% |
| 2020 Q1 | 7.4 Million SEK | 3.53% |
| 2020 Q2 | -43 Million SEK | -681.08% |
| 2020 FY | -47.96 Million SEK | -227.74% |
| 2020 Q3 | 20.2 Million SEK | 146.98% |
| 2019 Q3 | 20.3 Million SEK | 6666.67% |
| 2019 Q4 | 7.14 Million SEK | -64.79% |
| 2019 Q1 | 9.8 Million SEK | 584.84% |
| 2019 FY | 37.54 Million SEK | -8.49% |
| 2019 Q2 | 300 Thousand SEK | -96.94% |
| 2018 Q4 | 1.43 Million SEK | -85.4% |
| 2018 FY | 41.03 Million SEK | 10.18% |
| 2018 Q3 | 9.8 Million SEK | -34.23% |
| 2018 Q2 | 14.9 Million SEK | 0.0% |
| 2018 Q1 | 14.9 Million SEK | 85.35% |
| 2017 Q2 | -1.1 Million SEK | -112.64% |
| 2017 Q1 | 8.7 Million SEK | 507.12% |
| 2017 Q3 | 21.6 Million SEK | 2063.64% |
| 2017 Q4 | 8.03 Million SEK | -62.78% |
| 2017 FY | 37.23 Million SEK | 3.35% |
| 2016 Q2 | 9 Million SEK | 42.86% |
| 2016 Q3 | 19.3 Million SEK | 114.44% |
| 2016 Q4 | 1.43 Million SEK | -92.58% |
| 2016 Q1 | 6.3 Million SEK | 403.19% |
| 2016 FY | 36.03 Million SEK | 134.71% |
| 2015 Q3 | 5.1 Million SEK | 112.5% |
| 2015 Q1 | 6.6 Million SEK | -55.3% |
| 2015 Q4 | 1.25 Million SEK | -75.45% |
| 2015 Q2 | 2.4 Million SEK | -63.64% |
| 2015 FY | 15.35 Million SEK | -49.27% |
| 2014 Q2 | 1.7 Million SEK | -60.47% |
| 2014 Q4 | 14.76 Million SEK | 55.42% |
| 2014 FY | 30.26 Million SEK | 143.16% |
| 2014 Q1 | 4.3 Million SEK | 323.84% |
| 2014 Q3 | 9.5 Million SEK | 458.82% |
| 2013 FY | -70.12 Million SEK | -739.89% |
| 2013 Q2 | 5.9 Million SEK | 450.36% |
| 2013 Q4 | -1.92 Million SEK | 97.35% |
| 2013 Q3 | -72.41 Million SEK | -1327.37% |
| 2013 Q1 | -1.68 Million SEK | -151.55% |
| 2012 Q2 | 4.65 Million SEK | 613.34% |
| 2012 Q4 | 3.26 Million SEK | 263.0% |
| 2012 Q1 | -907 Thousand SEK | -130.67% |
| 2012 FY | 10.95 Million SEK | -6.42% |
| 2012 Q3 | 900 Thousand SEK | -80.67% |
| 2011 Q4 | 2.95 Million SEK | -64.89% |
| 2011 Q2 | -4.56 Million SEK | -197.02% |
| 2011 Q1 | 4.7 Million SEK | -37.14% |
| 2011 FY | 11.71 Million SEK | -38.01% |
| 2011 Q3 | 8.42 Million SEK | 284.61% |
| 2010 Q4 | 7.48 Million SEK | 192.98% |
| 2010 FY | 18.89 Million SEK | 279.09% |
| 2010 Q1 | 4.89 Million SEK | 0.0% |
| 2010 Q3 | -8.04 Million SEK | -155.14% |
| 2010 Q2 | 14.58 Million SEK | 198.1% |
| 2009 FY | -10.54 Million SEK | -90.09% |
| 2008 FY | -5.54 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | 132.088% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 75.868% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 75.868% |
| Arcoma AB | 2.56 Million SEK | -874.142% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 118.049% |
| BICO Group AB (publ) | -835.7 Million SEK | 102.989% |
| CellaVision AB (publ) | 130.3 Million SEK | 80.832% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | 131.303% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | 185.577% |
| C-Rad AB (publ) | 35.52 Million SEK | 29.7% |
| Duearity AB (publ) | -26.19 Million SEK | 195.368% |
| Dignitana AB (publ) | -17.36 Million SEK | 243.852% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 126.347% |
| Getinge AB (publ) | 2.41 Billion SEK | 98.964% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | 136.743% |
| Iconovo AB (publ) | -45.89 Million SEK | 154.423% |
| Integrum AB (publ) | 4.03 Million SEK | -519.396% |
| Luxbright AB (publ) | -25.37 Million SEK | 198.431% |
| Mentice AB (publ) | -2.81 Million SEK | 986.652% |
| OssDsign AB (publ) | -130.49 Million SEK | 119.14% |
| Paxman AB (publ) | 8.33 Million SEK | -199.844% |
| Promimic AB (publ) | -9.22 Million SEK | 370.841% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 115.615% |
| SciBase Holding AB (publ) | -55.58 Million SEK | 144.935% |
| ScandiDos AB (publ) | -14.64 Million SEK | 270.526% |
| Sectra AB (publ) | 428.38 Million SEK | 94.17% |
| Sedana Medical AB (publ) | -59.61 Million SEK | 141.899% |
| Senzime AB (publ) | -134.14 Million SEK | 118.619% |
| SpectraCure AB (publ) | -20.44 Million SEK | 222.191% |
| Stille AB | 26.64 Million SEK | 6.264% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 100.649% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 72.798% |